Förderungen und Zuschüsse für soziale Organisationen

NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Native American tribal governments (Federally recognized) · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · State governments · Small businesses · Special district governments · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

Vereinigte Staaten · US

Wer antragsberechtigt ist Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Private institutions of higher education · Small businesses · Special district governments · Independent school districts · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized) · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · City or township governments

The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

Vereinigte Staaten · US

Wer antragsberechtigt ist Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Private institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Public and State controlled institutions of higher education · County governments · Independent school districts

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Public and State controlled institutions of higher education · Independent school districts · For profit organizations other than small businesses · Small businesses · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education

This Notice of Funding Opportunity (NOFO) solicits applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on early-stage development from prototyping to initial dissemination. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving research projects and other users throughout the development process must be included.This NOFO encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness and potential impact on cancer research. In addition, all projects proposed in response to this NOFO must involve the following general attributes:Potential to advance driving cancer research projects and the cancer research field in generalNovel informatics capabilities for the targeted cancer research domainCompelling plans and processes for engaging end users to evaluate and apply the tool or resourceA realistic timeline and milestones for technology development

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Public and State controlled institutions of higher education

The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Vereinigte Staaten · US

Wer antragsberechtigt ist For profit organizations other than small businesses · Public housing authorities/Indian housing authorities · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Independent school districts · City or township governments · State governments · Special district governments · County governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification)

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Vereinigte Staaten · US

Wer antragsberechtigt ist Special district governments · City or township governments · Independent school districts · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Vereinigte Staaten · US

Wer antragsberechtigt ist Small businesses · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · County governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

Vereinigte Staaten · US

Wer antragsberechtigt ist Private institutions of higher education · Public and State controlled institutions of higher education

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate or advanced science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole.Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htmThis REAP Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Native American tribal governments (Federally recognized) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Special district governments · State governments · Small businesses · City or township governments

Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · Special district governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Private institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education

Reissue of PAR-20-118. This Notice of Funding Opportunity (NOFO) encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Others (see text field entitled "Additional Information on Eligibility" for clarification) · Independent school districts · State governments · Private institutions of higher education · Public and State controlled institutions of higher education · City or township governments · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · County governments · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses

The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Vereinigte Staaten · US

Wer antragsberechtigt ist Small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · For profit organizations other than small businesses · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

bases que rexerán o procedemento de concesión de axudas a entidades privadas para o fomento da gratuidade da atención educativa dos nenos e nenas da Comunidade Autónoma de Galicia en escolas infantís 0-3 para o curso 2026/2027 e se procede á súa convocato

AUTONOMICA - GALICIA - CONSELLERÍA DE POLÍTICA SOCIAL E IGUALDAD ·

Educación

Zeitraum: 28/7/2026 – —

Kennzeichnung von Projekten, die für eine EFRE-Förderung zur Unterstützung der Biodiversität und des Hochwasserschutzes im Seine-Becken in Frage kommen

Frankreich · FR

Wer antragsberechtigt ist Commune · Intercommunalité / Pays · Département · Etablissement public dont services de l'Etat · Entreprise publique locale (Sem, Spl, SemOp)

Dieser von der Direction régionale et interdépartementale de l'environnement, de l'aménagement et des transports (DRIEAT) gestartete Projektaufruf zielt darauf ab, Projekte zu kennzeichnen, die im Rahmen des Regionalprogramms 2021-2027 für eine EFRE-Förderung zur Unterstützung der Biodiversität und des Hochwasserschutzes im Seine-Becken in Frage kommen. Das Budget für das Thema ökologische Kontinuitäten beträgt 3,5 Millionen Euro. DIE ZIELE DES PROJEKTAUFrufs Dieser Projektaufruf zielt darauf ab, Maßnahmen zu initiieren und vorab auszuwählen, die zur Wiederherstellung der ökologischen Kontinuität von Wasserläufen beitragen, um Wanderachsen zurückzugewinnen. Die Maßnahmen entsprechen den folgenden Zielen: Verbesserung der Kontinuität der Wasserläufe, um Wanderfischen die Erweiterung ihres Verbreitungsgebiets zu ermöglichen Sicherstellung der Überwachung der Populationen und der Entwicklung des Wissens über die verschiedenen Arten Wiederherstellung der Populationen amphialiner Wanderfische im Seine-Becken und an den normannischen Küsten

Zeitraum: 5/6/2024 – —

Kennzeichnung von Projekten, die für eine EFRE-Förderung zur Unterstützung der Biodiversität und des Hochwasserschutzes im Seine-Becken in Frage kommen

Frankreich · FR

Wer antragsberechtigt ist Commune · Département · Etablissement public dont services de l'Etat

Dieser von der DRIEAT gestartete Projektaufruf zielt darauf ab, Projekte zu kennzeichnen, die im Rahmen des Regionalprogramms 2021-2027 für eine EFRE-Förderung zur Unterstützung der Biodiversität und des Hochwasserschutzes im Seine-Becken in Frage kommen. Der für Hochwasserschutz vorgesehene Betrag beläuft sich auf 5,5 Millionen Euro. DIE ZIELE DES PROJEKTAUFRUFS Dieser Projektaufruf zielt darauf ab, Maßnahmen zu initiieren und vorab auszuwählen, die mindestens einem der 3 Hauptziele des Hochwasserrisikomanagementplans für das Seine-Normandie-Becken entsprechen, nämlich: Gebiete widerstandsfähig zu gestalten, um ihre Anfälligkeit zu verringern; Auf die Gefahr einzuwirken, um die Sicherheit von Personen zu erhöhen und die Kosten von Schäden zu reduzieren; Alle Akteure für das Wissen und die Risikokultur zu mobilisieren.

Zeitraum: 5/6/2024 – —

Open topic on research and innovation for effective management of EU external borders that promotes fundamental rights and EU values

Europäische Union · EU

Open topic on research and innovation for effective management of EU external borders that promotes fundamental rights and EU values

Zeitraum: 5/5/2027 – —

Trusted, secure, quality future digital travel credentials

Europäische Union · EU

Trusted, secure, quality future digital travel credentials

Zeitraum: 5/5/2027 – —

Detection and characterisation of threats or illegal/ smuggled goods in cargo

Europäische Union · EU

Detection and characterisation of threats or illegal/ smuggled goods in cargo

Zeitraum: 5/5/2027 – —

Open Topic on advanced protective gear optimized for CBRN-E (Chemical, Biological, Radiological, Nuclear, Explosives) environments and new generation of smart protective equipment for disaster responders

Europäische Union · EU

Open Topic on advanced protective gear optimized for CBRN-E (Chemical, Biological, Radiological, Nuclear, Explosives) environments and new generation of smart protective equipment for disaster responders

Zeitraum: 5/5/2027 – —

Societal resilience, engagement of the younger generations and digital innovation for disaster resilience

Europäische Union · EU

Societal resilience, engagement of the younger generations and digital innovation for disaster resilience

Zeitraum: 5/5/2027 – —

Enhancing decision support system for disaster crises: leveraging emerging technologies for improved civil preparedness and crisis management

Europäische Union · EU

Enhancing decision support system for disaster crises: leveraging emerging technologies for improved civil preparedness and crisis management

Zeitraum: 5/5/2027 – —

Enhancing preparedness for large-scale cross-border disasters

Europäische Union · EU

Enhancing preparedness for large-scale cross-border disasters

Zeitraum: 5/5/2027 – —

Online harms detection and investigation tools using a short development cycle model

Europäische Union · EU

Online harms detection and investigation tools using a short development cycle model

Zeitraum: 5/5/2027 – —